Crysalin develop a protein lattice technology that is founded on a novel form of highly ordered materials, crysalins, that are produced through modification of naturally occurring protein building blocks.

Oxford BioDynamics offers a novel and revolutionary biomarker discovery platform technology in the diagnostics field of aberrant gene expression.

ClinOx offers clients knowledge and expertise in the development, placement, conduct and analysis of early phase oncology clinical trials, with particular emphasis on pharmacokinetic and mechanistic endpoints.

Eykona develops state-of-the-art imaging solutions to capture dermal characteristics and shape from the human body.

Oxtox develops medical devices for the detection of specific drugs in the human system.

Cytox develops a technology platform for tests to identify individuals at risk of cognitive decline, Alzheimer’s disease and other dementias.

Oxford Advanced Surfaces develops and commercialises advanced materials and technology solutions leveraging breakthrough surface modification technology.

Aurox was established to research, develop, manufacture and commercially exploit products in the field of confocal microscopy and automated pathology slide scanners.

Particle Therapeutics is a drug delivery company developing innovative particle formulation and drug delivery technologies to improve the efficacy and administration of a range of pharmaceuticals.

Big data and analysis company focused on enabling reproducibility in chemistry.

Oxford Medistress is commercialising a novel in vitro blood test device which aims to provide the first objective, quantitative measurement of stress.

TdeltaS is committed to developing science-based proprietary products that sit at the interface of food and pharmaceuticals - nutraceuticals - and offer real improvement in human physical and mental performance.

Velocys, previously Oxford Catalysts, produces speciality catalysts for the generation of clean fuels, from both conventional fossil fuels and renewable sources such as biomass.

Celleron is an oncology healthcare company that has developed biomarkers using epigenetic techniques that match drugs to responsive disease.

Oxbridge Pulsar Sources (OPS) is researching and developing novel radio transmitting antennas, based on new principles.

Robust, networked sensors for oilfield machinery, drilling and metering.

Oxford Nanopore Technologies is developing and commercialising a new generation of nanopore-based electronic systems for analysis of single molecules, including DNA, RNA and proteins.

EKB Technology commercialises a revolutionary Bioprocessing Technology developed for the use of biological systems such as plant and animal cells and microorganisms to modify, produce or purify chemical intermediates.

Surface Therapeutics is a drug discovery and development company developing innovative new drugs to treat inflammatory epithelial diseases of the skin and lungs. Surface Therapeutics was acquired by Serentis Inc in September 2007.

G-Nostics has identified SNPs that have highly predictive associations with nicotine addiction and therefore tobacco consumption. These SNPs provide a method to help individuals decide which specific smoking cessation methods are most effective for them, offering personalised treatment to the 'smoker' which significantly increases their chances of quitting.